{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T03:06:50Z","timestamp":1770347210875,"version":"3.49.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["RO1 HL081893"],"award-info":[{"award-number":["RO1 HL081893"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.atherosclerosis.2013.07.001","type":"journal-article","created":{"date-parts":[[2013,7,13]],"date-time":"2013-07-13T02:15:13Z","timestamp":1373681713000},"page":"121-124","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance"],"prefix":"10.1016","volume":"230","author":[{"given":"Kevin D.","family":"Ballard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beth A.","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey A.","family":"Capizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam S.","family":"Grimaldi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Priscilla M.","family":"Clarkson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie M.","family":"Cole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justin","family":"Keadle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Chipkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda S.","family":"Pescatello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. Michael","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul D.","family":"Thompson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib2","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1161\/CIRCULATIONAHA.112.136101","article-title":"Effect of statins on skeletal muscle function","volume":"127","author":"Parker","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib3","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0002-9149(93)90858-A","article-title":"Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8\u00a0mmol\/liter (200 to 300\u00a0mg\/dl) plus two additional atherosclerotic risk factors. The pravastatin multinational study group for cardiac risk patients","volume":"72","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib4","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/0002-9149(94)90307-7","article-title":"Expanded clinical evaluation of lovastatin (EXCEL) study results: two-year efficacy and safety follow-up","volume":"74","author":"Bradford","year":"1994","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib5","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib6","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMp1112023","article-title":"Needed: pragmatic clinical trials for statin-intolerant patients","volume":"365","author":"Maningat","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib7","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/0735-1097(95)00301-0","article-title":"Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation","volume":"26","author":"Pitt","year":"1995","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib8","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1001\/jama.287.24.3215","article-title":"Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: a randomized controlled trial","volume":"287","author":"Serruys","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib9","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/euhj.1998.1150","article-title":"A\u00a0randomized placebo-controlled trial of fluvastatin for prevention of restenosis after successful coronary balloon angioplasty; final results of the fluvastatin angiographic restenosis (FLARE) trial","volume":"20","author":"Serruys","year":"1999","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib10","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.amjcard.2011.08.045","article-title":"Effect of statins on creatine kinase levels before and after a marathon run","volume":"109","author":"Parker","year":"2012","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib11","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1016\/S0026-0495(97)90218-3","article-title":"Lovastatin increases exercise-induced skeletal muscle injury","volume":"46","author":"Thompson","year":"1997","journal-title":"Metabolism"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib12","unstructured":"Ganga HV, Slim J and Thompson PD. A systematic review of statin-induced muscle problems in clinical trials. Unpublished work."},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib13","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1001\/archinte.1993.00410110029006","article-title":"Comparative efficacy and safety of pravastatin and cholestyramine alone and combined in patients with hypercholesterolemia. Pravastatin multicenter study group II","volume":"153","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib14","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1093\/oxfordjournals.eurheartj.a060485","article-title":"Three-year follow-up of the oxford cholesterol study: assessment of the efficacy and safety of simvastatin in preparation for a large mortality study","volume":"15","author":"Keech","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib15","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1001\/archinte.1996.00440170097011","article-title":"Safety and tolerability of cholesterol lowering with simvastatin during 5 years in the Scandinavian simvastatin survival study","volume":"156","author":"Pedersen","year":"1996","journal-title":"Arch Intern Med"},{"issue":"Pt 4","key":"10.1016\/j.atherosclerosis.2013.07.001_bib16","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/000456328802500411","article-title":"Body composition and plasma creatine kinase activity","volume":"25","author":"Swaminathan","year":"1988","journal-title":"Ann Clin Biochem"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib17","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1007\/s100670070049","article-title":"Serum creatine kinase in patients with rheumatic diseases","volume":"19","author":"Lee","year":"2000","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib18","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/01.ATV.0000043456.48735.20","article-title":"HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells","volume":"23","author":"Dichtl","year":"2003","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib19","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1152\/japplphysiol.00130.2005","article-title":"ACTN3 and MLCK genotype associations with exertional muscle damage","volume":"99","author":"Clarkson","year":"2005","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib20","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1152\/japplphysiol.00361.2009","article-title":"CCL2 and CCR2 polymorphisms are associated with markers of exercise-induced skeletal muscle damage","volume":"108","author":"Hubal","year":"2010","journal-title":"J\u00a0Appl Physiol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.atherosclerosis.2009.11.033","article-title":"The genetics of statin-induced myopathy","volume":"210","author":"Ghatak","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib22","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib23","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1111\/j.1742-7843.2006.pto_193.x","article-title":"Muscle symptoms associated with statins: a series of twenty patients","volume":"98","author":"Soininen","year":"2006","journal-title":"Basic Clin Pharmacol Toxicol"},{"key":"10.1016\/j.atherosclerosis.2013.07.001_bib24","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013003936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915013003936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T00:34:46Z","timestamp":1758155686000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915013003936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":24,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0021915013003936"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.07.001","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Increases in creatine kinase with atorvastatin treatment are not associated with decreases in muscular performance","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2013.07.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ireland Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}